Our approach to research is the opposite of the traditional approach.The traditional method of drug discovery starts from a “top down” approach – looking for active compounds, screening them, then gradually following all the steps needed to start a clinical trial.With Cannabinoids, the safety is already well established, and the use is widespread. The top down approach cannot be successful.Our approach is to look at the data of what is actually happening in our patients – starting with a wide field of examination and focusing on the most clearly successful areas of treatment.Our extended groups of practitioners include every professional group from consultant neurologists, paediatricians, rheumatologists, dermatologists, general practitioners, prescribing associated healthcare professions and physiotherapists.To find out more information about research ongoing in each category, please have a look through our menus.

1 of 8

Chronic Fatigue and Auto Immune

Our aim is to retrospectively analyse patient events, where supply events have occurred to patients who have pain caused by an underlying inflammatory disease.

2 of 8

Bowel Disease IBD

Our aim in this arm of the research is to capture patients with self-reported conditions, currently on no or standard therapy, and see whether cannabidiol provides a safe extension to the period of remission.

3 of 8

Inflammatory Pain Conditions

Our aim is to capture data from patients who have switched from THC containing cannabis products, to non-THC cannabis products – and determine if the efficacy and symptom control are similar.

Canidol used for Multiple Sclerosis
4 of 8

Multiple Sclerosis

Our aim is to capture data from patients who have switched from THC containing cannabis products, to non-THC cannabis products – and determine if the efficacy and symptom control are similar.

5 of 8

Hospice Care

Currently, a reportedly huge problem facing hospices and oncology wards worldwide, is that patients are obtaining illegal cannabis preparations and taking them into hospital.

Canidol used in Paediatric patients
6 of 8

Pediatric Use

The aim of this set of research is not to determine efficacy, but to determine if there is a dose/side effect profile in paediatric patients under the direct care of a consultant paediatrician.

7 of 8

Oncology and Cancer

Under the direction of our consultant oncologists, the aim is to examine data based on supplies of cannabinoids made to patients - using standardised dosing - extrapolated from in-vitro studies.

8 of 8

Historical Research

Our aim is to capture data from patients who have switched from THC containing cannabis products, to non-THC cannabis products – and determine if the efficacy and symptom control are similar.